Sign In
Buy LQDA
$55.69
+0.580 (+1.05%)
At Close: Jun 03, 2026
An Investigation Has Commenced on Behalf of Liquidia Corporation Shareholders. Contact Levi & Korsinsky to Discuss your LQDA Losses
11:30am, Thursday, 22'nd Aug 2024
NEW YORK, NY / ACCESSWIRE / August 22, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Liquidia Corporation ("Liquidia Corporation") (NASDAQ:LQDA) concerning possi
Shareholders With Losses In Liquidia Corporation Are Encouraged To Join The Schall Law Firm In A Securities Fraud Investigation
11:00am, Thursday, 22'nd Aug 2024
LOS ANGELES, CA / ACCESSWIRE / August 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Liquidia Corpor
Levi & Korsinsky Announces an Investigation on Behalf of Liquidia Corporation (LQDA) Shareholders Who May Have Been Affected by Fraud
07:25am, Thursday, 22'nd Aug 2024
NEW YORK, NY / ACCESSWIRE / August 22, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Liquidia Corporation ("Liquidia Corporation") (NASDAQ:LQDA) concerning possi
Liquidia challenges regulatory exclusivity for rival's inhaled drug
06:21am, Thursday, 22'nd Aug 2024
Liquidia Corp has filed a legal challenge to the U.S. Food and Drug Administration's decision to grant three-year exclusivity to United Therapeutics' inhaled drug used to treat lung disorders, it said
MORRISVILLE, N.C., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, an
Liquidia (LQDA) Down on FDA Delaying Full Approval for Yutrepia
11:31am, Tuesday, 20'th Aug 2024
The FDA grants tentative approval to Liquidia's (LQDA) inhaled powder for two lung disorder indications. Full approval may be granted after May 2025, when the regulatory exclusivity of a competing pro
LQDA ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you Lost Money on your Liquidia Corporation Investment
11:15am, Tuesday, 20'th Aug 2024
NEW YORK, NY / ACCESSWIRE / August 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Liquidia Corporation ("Liquidia Corporation") (NASDAQ:LQDA) concerning possi
LQDA Investors Invited To Participate In Liquidia Corporation Securities Fraud Investigation With The Schall Law Firm
11:00am, Tuesday, 20'th Aug 2024
LOS ANGELES, CA / ACCESSWIRE / August 20, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Liquidia Corpor
These Analysts Cut Their Forecasts On Liquidia
08:15am, Tuesday, 20'th Aug 2024
Liquidia Corporation LQDA, on Monday, announced that the Food and Drug Administration (FDA) granted tentative approval of YUTREPIA.
NEW YORK, NY / ACCESSWIRE / August 19, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Liquidia Corporation ("Liquidia Corporation") (NASDAQ:LQDA) concerning possi
Liquidia Corp. Investigated for Securities Fraud; Block & Leviton Encourages Investors Who Have Lost Money to Contact the Firm
10:42am, Monday, 19'th Aug 2024
Block & Leviton is investigating Liquidia (Nasdaq: LQDA) for potential securities law violations. Investors who have lost money should contact the firm.
Liquidia, Shake Shack And Other Big Stocks Moving Lower In Monday's Pre-Market Session
08:27am, Monday, 19'th Aug 2024
U.S. stock futures were slightly higher this morning, with the S&P 500 futures gaining around 0.1% on Monday.
US FDA grants tentative approval to Liquidia's inhaled blood pressure drug
06:16am, Monday, 19'th Aug 2024
The U.S. Food and Drug Administration has granted tentative approval to Liquidia Corp's drug to treat high blood pressure in the lungs, and for patients with a type of lung disorder, the company said
FDA confirmed that the amendment to add PH-ILD to the YUTREPIA NDA was proper and that application otherwise meets the requirements for approval under the Federal Food, Drug, and Cosmetic Act Final Ap
Liquidia Announces Poster Presentations at the PHA 2024 International PH Conference and Scientific Sessions
06:30am, Friday, 16'th Aug 2024
Liquidia Corporation (NASDAQ: LQDA) will present nine encore thematic posters at the 2024 Pulmonary Hypertension Association (PHA) International Conference
